Cyfuse Biomedical K.K. (JP:4892)
:4892
Want to see JP:4892 full AI Analyst Report?
Top Page
Cyfuse Biomedical K.K.
(4892)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥532.00
▼(-9.83% Downside)
Action:Reiterated
Date:02/18/26
The score is held down primarily by weak financial performance—deep losses and ongoing negative free cash flow—despite a strong revenue rebound and manageable leverage. Technicals are moderately supportive with improving short-to-mid-term trend and constructive momentum, while valuation remains constrained by unprofitability and no dividend yield provided.
Positive Factors
Strong revenue rebound
Revenue surged 253% YoY in 2025 to ~231m, signaling renewed commercial traction for products and services. A durable top-line increase supports scale economies, helps absorb fixed R&D costs, and improves the potential for sustained margin recovery as the business executes commercialization.
Negative Factors
Persistent negative cash flow
Operating cash flow (~-535m) and free cash flow (~-582m) in 2025 show continued cash burn despite revenue growth. Persistent negative cash generation necessitates external financing, raising dilution and refinancing risk and limiting the company's ability to self-fund scaling or endure prolonged R&D cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue rebound
Revenue surged 253% YoY in 2025 to ~231m, signaling renewed commercial traction for products and services. A durable top-line increase supports scale economies, helps absorb fixed R&D costs, and improves the potential for sustained margin recovery as the business executes commercialization.
Read all positive factors
Cyfuse Biomedical K.K. (4892) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.42B
Dividend YieldN/A
Average Volume (3M)50.89K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue Growth246.42%
EPS Growth9.39%
CountryJP
Employees21
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-101.10
Shares Outstanding10,091,200
10 Day Avg. Volume43,580
30 Day Avg. Volume50,893
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.88
Price to Sales (P/S)22.48
P/FCF Ratio-8.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cyfuse Biomedical K.K. Business Overview & Revenue Model
Company Description
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeu...
How the Company Makes Money
Cyfuse Biomedical makes money primarily by commercializing its 3D cell assembly platform and related offerings to customers engaged in life science research and regenerative medicine development. Revenue is generated through (1) sales of products ...
Cyfuse Biomedical K.K. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.82M | 231.00M | 54.45M | 61.11M | 374.48M | 708.25M |
| Gross Profit | -3.23M | 78.40M | 1.56M | -378.00K | 223.93M | 568.20M |
| EBITDA | -883.27M | -792.68M | -860.12M | -659.31M | -370.81M | 89.07M |
| Net Income | -827.55M | -763.84M | -872.24M | -589.21M | -473.96M | 142.91M |
Balance Sheet | ||||||
| Total Assets | 3.23B | 4.27B | 3.52B | 4.21B | 4.82B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 2.70B | 3.73B | 3.05B | 3.87B | 4.44B | 2.41B |
| Total Debt | 766.00M | 1.31B | 852.80M | 913.00M | 857.79M | 569.06M |
| Total Liabilities | 901.89M | 1.51B | 975.60M | 1.01B | 1.05B | 746.12M |
| Stockholders Equity | 2.33B | 2.76B | 2.54B | 3.20B | 3.77B | 1.90B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -581.93M | -768.16M | -581.77M | -631.87M | 161.54M |
| Operating Cash Flow | 0.00 | -534.79M | -760.55M | -562.30M | -403.60M | 161.54M |
| Investing Cash Flow | 0.00 | -397.56M | -8.64M | -19.47M | -430.67M | -50.58M |
| Financing Cash Flow | 0.00 | 1.26B | -52.01M | 18.24M | 2.66B | 229.21M |
Cyfuse Biomedical K.K. Technical Analysis
Negative
590.00
Price Trends
625.66
Negative
634.89
Negative
616.02
Negative
Market Momentum
-27.21
Positive
32.69
Neutral
20.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4892, the sentiment is Negative. The current price of 590 is above the 20-day moving average (MA) of 583.20, below the 50-day MA of 625.66, and below the 200-day MA of 616.02, indicating a bearish trend. The MACD of -27.21 indicates Positive momentum. The RSI at 32.69 is Neutral, neither overbought nor oversold. The STOCH value of 20.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4892.
Cyfuse Biomedical K.K. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥6.19B | 9.12 | ― | 3.00% | -9.59% | -25.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥5.52B | 27.79 | ― | 3.21% | 1.60% | -32.76% | |
48 Neutral | ¥5.42B | -6.47 | ― | ― | 246.42% | 9.39% | |
42 Neutral | ¥6.28B | -6.93 | -90.96% | ― | 24.62% | 60.41% | |
42 Neutral | ¥3.28B | -1.66 | ― | ― | ― | 14.26% | |
41 Neutral | ¥5.34B | -0.80 | ― | ― | -39.73% | -9.00% |
* Healthcare Sector Average
JP:4892
Cyfuse Biomedical K.K.
537.00
-376.00
-41.18%
JP:4597
Solasia Pharma KK
23.00
-7.00
-23.33%
JP:4539
Nippon Chemiphar Co., Ltd.
1,528.00
90.87
6.32%
JP:4582
Symbio Pharmaceuticals Limited
70.00
-104.00
-59.77%
JP:4883
Modalis Therapeutics Corporation
34.00
-58.00
-63.04%
JP:7079
WDB coco Co., Ltd.
2,575.00
-336.20
-11.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.